Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Declines By 12.9%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 16,200 shares, a decline of 12.9% from the June 15th total of 18,600 shares. Based on an average daily volume of 41,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.9% of the shares of the company are sold short.

Lixte Biotechnology Trading Up 0.4 %

NASDAQ LIXT opened at $2.38 on Friday. Lixte Biotechnology has a 1 year low of $1.58 and a 1 year high of $9.50. The company has a fifty day simple moving average of $2.45 and a 200 day simple moving average of $2.54. The company has a market cap of $5.36 million, a P/E ratio of -1.02 and a beta of -0.21.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.43) earnings per share for the quarter.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.